louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05171933: Stress Factors and Vaccine Attitudes Among Dental Students During COVID-19
Official title: Educational Status, Stress Factors and Vaccine Attitudes Among Dental Students During COVID-19 Pandemic in Turkey
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Surveys and Questionnaires
Keywords: COVID-19
vaccine
anxiety
concern
dental students
Lead sponsor: Yuzuncu Yıl University
Sponsor class: OTHER
First posted: 2021-12-29
Enrollment: 579
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Dental studentS in Turkey

Brief summary: Background: The aim of this study is to investigate the impact of the COVID-19 pandemic on the education of dental students in Turkey, the reasons that affect the psychological attitudes of students towards this disease, stress factors and the effect of these factors on vaccine acceptance.

Methods: The survey was applied online and consisted of questions aimed to find out the demographic characteristics, educational status, anxiety-stress factors, and reasons for students' decision behind COVID-19 vaccine administration. The psychological impact of COVID-19 was assessed by means of the Generalised Anxiety Disorder-7 scale (GAD-7). Standard descriptive statistics, the chi-square test and independent samples t test were used for statistical analysis.

Detailed description: An online survey was conducted among dentistry students in Turkey between April-May 2021. Participants were included in the survey on the condition that they were enrolled in a dental school in Turkey at the time.

Participation in the survey was completely voluntary. Participants got the link to the survey online and accessed it directly by clicking the link. At the beginning of the survey, participants were informed that their participation was voluntary, their answers were anonymous, and they could leave at any time. They were then explicitly asked if they wanted to participate in the research study before starting the survey. The survey was created using the free-to-access Google Forms app and took approximately 15 minutes to complete.

Survey consisted of questions about the effects of COVID-19 epidemic on the education of dental students in Turkey, stress factors, the reasons and factors affecting their psychological attitudes towards this disease. There were also questions about the effects of these reasons/factors on attitudes and behaviors related to vaccination.

Eligibility criteria: Inclusion Criteria: To be a dental student in Turkey -

Exclusion Criteria:

-

Primary outcomes:
measure: Educational Status, Stress Factors and Vaccine Attitudes among Dental Students during COVID-19 Pandemic in Turkey
timeFrame: April-May 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Van
country: Turkey
facility: Yuzuncu Yil University
Study officials:
References:
Clinical trial NCT05498987: Ultrasound Achilles Tendon Assessment
Official title: Ultrasound Achilles Tendon Assessment After 448kilohertz Capacitive Resistive Radiofrequency Stimulation in a Sporty Population
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Ultrasonography
Achilles Tendon
Lead sponsor: Universidad de Granada
Sponsor class: OTHER
First posted: 2022-08-12
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: 448kilohertz capacitive resistive monopolar radiofrequency is a novel technique in physiotherapy and its usefulness and clinical relevance is still to be investigated at both clinical practice and also in performance. Current studies show promising results in different musculoskeletal disorders, however there no studies in the assessment of quality soft tissue in sporty population after the used of this technique.

Detailed description: Achilles Tendon pain is is one of the most common musculoskeletal disorders, presenting a high prevalence in primary care centers and sport populations. Many factors have been proposed as the cause of pain, however there are no studies analysing possibilities of preventing Achilles Tendon injuries by using a radiofrequency stimulus.

The use of 448kilohertz capacitive resistive monopolar radiofrequency as the focus of the treatment looking for improve the quality of the tissue is still to be explored.

The hypothesis of the present project is that focus treatments on 448kilohertz capacitive resistive monopolar radiofrequency on the Achilles Tendon will produce better outcomes in terms of ultrasound assessment measured by quantified elastography, and this will decreased the possibilities of get injured.

The stimulus will be carried out on the Achilles Tendon region. All interventions will be developed by the same examiner, who is a physiotherapist with 6 years of clinical experience.

Eligibility criteria: Inclusion Criteria:

* Age between 18-50 years
* Sporty people with at least 3 days of training per week and presenting an upper limb dominance.

Exclusion Criteria:

* Suffer from any painful Achilles Tendon condition.
* History of significant Achilles Tendon trauma, such as fracture or ultrasonography Clinically suspected partial thickness cuff tear, following the classification of Wiener and Seitz.

Primary outcomes:
measure: Change from Baseline in Achilles Tendon measured by quantified elastography imaging at 3 months. time (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later).
timeFrame: time (t) 1(prior to treatment), t2 (immediately after the treatment), t3 (3 months later). Changes in tendinous thickness [ Time Frame: 9 months ]
Secondary outcomes:
Other outcomes:
Locations:
city: Málaga
country: Spain
facility: Ana Gonzalez Muñoz
state: Malaga
Study officials:
References:
Clinical trial NCT03383887: DAW1033D in Obstructive Sleep Apnea
Official title: Effect of DAW1033D on Obstructive Sleep Apnea and Its Phenotypic Traits
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Obstructive Sleep Apnea (OSA)
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
First posted: 2017-12-27
Enrollment: 11
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of DAW1033D administered before sleep on OSA phenotype traits and OSA severity during sleep.


Eligibility criteria: Inclusion Criteria:

- AHI \> 15

Exclusion Criteria:

* Any medical condition other than well controlled hypertension, diabetes, hyperlipidemia
* Any medication known to influence breathing, sleep/arousal or muscle physiology.
* Claustrophobia.
* Inability to sleep supine.
* Allergy to lidocaine, Oxymetazoline HCl, DAW1033D.
* Individuals with underlying cardiac disease, such as arrhythmias.
* Individuals taking psychiatric medications, or any of the studied medications for medical care.
* History of seizures
* For women: Pregnancy.
* History of panic disorder / hyperventilation syndrome / Attention deficit-hyperactivity disorder (ADHD) / autism

Primary outcomes:
measure: Apnea Hypopnea Index (AHI, Events/Hour of Sleep)
timeFrame: 1 night
Secondary outcomes:
measure: Collapsibility of the Upper Airway: VPassive
timeFrame: 1 night
Other outcomes:
Locations:
city: Boston
country: United States
facility: Sleep Disorders Research Program Brigham and Women's Hospital
state: Massachusetts
Study officials:
References:
citation: Taranto-Montemurro L, Sands S, Azarbarzin A, Calianese N, Vena D, Hess L, Kim SW, White DP, Wellman A. Impact of cold and flu medication on obstructive sleep apnoea and its underlying traits: A pilot randomized controlled trial. Respirology. 2021 May;26(5):485-492. doi: 10.1111/resp.14009. Epub 2021 Jan 24.
Clinical trial NCT01511887: Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA)
Official title: Evaluation of the Safety and Efficacy of Oral Ibuprofen in Term 20-28 Days Old Newborns Referred to Bandar Abbass Children Hospital in 2011
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patent Ductus Arteriosus
Keywords: Patent Ductus Arteriosus
PDA
Term newborns
Ibuprofen
Lead sponsor: Hormozgan University of Medical Sciences
Sponsor class: OTHER
First posted: 2012-01-19
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 28
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of current study is to evaluate the efficacy and safety of oral Ibuprofen in term 20-28 days old newborn referred to Bandarabbas children' hospital in 2011.

Detailed description: Patent Ductus Arteriosus (PDA) accounts for about 10% of Congenital Heart Disease. Surgical treatment in PDA is associated with higher rate of complication than pharmacologic treatment. Efficacy of Ibuprofen is shown in preterm and low birth weights newborn with PDA. Studies in term neonates after the first days of birth are rare. The aim of current study is to evaluate the efficacy and safety of oral Ibuprofen in term 20-28 days old newborn referred to Bandarabbas children' hospital in 2011.

Eligibility criteria: Inclusion Criteria:

* Term newborn (37 weeks of gestation or more)
* Age between 20-28 days
* confirmed diagnosis of PDA by echocardiography by pediatric cardiologist

Exclusion Criteria:

* Asphyxia
* Hemorrhage
* Platelet count \< 150000
* renal or gastrointestinal malformations
* associated congenital heart disease

Primary outcomes:
measure: PDA closure after 1 week
timeFrame: 1 weeks after treatment
measure: PDA closure after two weeks
timeFrame: 2 weeks after treatment
Secondary outcomes:
measure: Drug side effects
timeFrame: two weeks after treatment
Other outcomes:
Locations:
city: Bandar Abbas
country: Iran, Islamic Republic of
facility: Hormozgan University of Medical Sciences
state: Hormozgan
Study officials:
affiliation: Hormozgan University of Medical Sciences (HUMS)
name: Hamidreza Mahboobi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05680987: Retrograde Femoral Nail-Advanced Outcomes for Fixation of Distal Femur and Femoral Shaft Fractures
Official title: Utilizing the Retrograde Femoral Nail-Advanced for Fixation of Distal Femur and Femoral Shaft Fractures: A Prospective Case Series
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Femoral Fracture
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
Collaborators: name: DePuy Synthes
First posted: 2023-01-11
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This project consists of a prospective and retrospective case series design. Study candidates will include all patients 18 years or older, who were evaluated at UCSD and found to have a distal femur or femoral shaft fracture requiring surgical fixation. Patients who consent to study participation will recieve the RFN-advanced Retrograde Femoral Nailing System implant for fracture fixation. Data on functional status, healing rates, complication rates, and pain levels will be collected for each participant. After 3 years of data collection, investigators will analyze this data to provide further insight on the utility of this new design of retrograde femoral nails. Given the relatively high rate of complications, such as malalignment, with current femoral nail designs, it is imperative to evaluate novel systems to appropriately manage distal femur or femoral shaft fractures.


Eligibility criteria: Inclusion Criteria:

* Distal femur or femoral shaft fracture requiring surgery
* Evaluation and treatment at UCSD
* Age 18 years or older
* Ability to understand the content of the patient information/Informed Consent Form
* Signed and dated IRB-approved written informed consent

Exclusion Criteria:

* Any not medically managed severe systemic disease
* their doctor has decided that it is in the patient's best interest to receive a different method of fixation
* Their doctor has determined that the patient has a condition that would make them unsuitable for participation in the study
* Pregnancy or women planning to conceive within the subject participation period (1 year) note: pregnancy will be self-reported and no test will be performed to test for it
* Prisoner
* Participation in any other pharmacologic or medicinal product study within the previous month that could influence the results of this study

Primary outcomes:
measure: Healing Rates
timeFrame: 2 years
Secondary outcomes:
measure: Pain Score (0-10,0=no pain, 10=most severe)
timeFrame: 1 year
measure: Number of Complications
timeFrame: 1 year
Other outcomes:
Locations:
city: San Diego
country: United States
facility: University of California, San Diego
state: California
Study officials:
References:
Clinical trial NCT03043287: Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)
Official title: Voiding Efficiency, a Predictor of CIC
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Urinary Bladder, Overactive
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2017-02-06
Enrollment: 420
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients treated with BOTOX® for Idiopathic OAB in clinical practice.

Brief summary: This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.


Eligibility criteria: Inclusion Criteria:

* Patient with documented idiopathic OAB diagnosis
* Patient was treated with 100-200U of BOTOX® for OAB
* Urodynamics assessment within prior to first BOTOX® injection.

Exclusion Criteria:

* Patient had received botulinum toxin formulations other than BOTOX® in the bladder
* Patient had symptoms of OAB associated with a neurological condition (eg, spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc).

Primary outcomes:
measure: Pre-BOTOX® Injection VE Cutoff-Ratios that Predict the Risk of CIC following Treatment with 100-200U of BOTOX®
timeFrame: Pre-BOTOX® Injection (Baseline)
measure: Length of Time of CIC Use in Clinical Practice after Treatment with 100-200U BOTOX®
timeFrame: 12 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Shreveport
country: United States
facility: Regional Urology
state: Louisiana
city: Baltimore
country: United States
facility: Chesapeake Urology Associates, LLC
state: Maryland
city: Richmond
country: United States
facility: Virginia Urology
state: Virginia
Study officials:
affiliation: Allergan
name: Dana Fetterolf
role: STUDY_DIRECTOR
References:
Clinical trial NCT00250887: Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research
Official title: A Phase II Open Label Study of the Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Recurrent Glioblastoma
Keywords: recurrent Glioblastoma, Gefitinib
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2005-11-08
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy). Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR). EGFR is elevated in more than 50% of malignant gliomas. At recurrence, secondary surgery and pre- and postoperative Gefitinib is offered to patients in good performance status. Clinical outcome of patients and correlation to translational research will be evaluated.

Detailed description: Glioblastoma (GBM) patients who relapse and are in good performance status, without serious neurological deficits are offered secondary surgery and participation in the trial. Eligible patients must have had standard treatment including primary surgery, radiation therapy and at least a first line chemotherapy. Patients on cytochrome P450 isoenzyme CYP3A4-inducing antiepileptic drugs (EIAE) are excluded due to ensuing interactions of these drugs with gefitinib metabolism, reducing systemic availability. After giving written informed consent, patients receive gefitinib 500 mg daily starting at least 5 days prior to re-operation, allowing a steady state condition.Treatment continues until tumor progression or occurrence of intolerable side effects.The specimens collected at surgery will undergo translational research, aiming to correlate drug accumulation and molecular signatures of GBM samples with clinical outcome.

Eligibility criteria: Inclusion Criteria:

* recurrent glioblastoma
* informed consent
* reoperation planned
* fresh frozen sample obtainable

Exclusion Criteria:

* enzyme inducing antiepileptic drugs
* pregnancy or breast feeding

Primary outcomes:
measure: molecular signature of EGFR responsiveness to ZD1839
Secondary outcomes:
measure: PFS
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: University Hospital Zürich
Study officials:
affiliation: University Hospital, Zürich
name: Silvia Hofer, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hegi ME, Diserens AC, Bady P, Kamoshima Y, Kouwenhoven MC, Delorenzi M, Lambiv WL, Hamou MF, Matter MS, Koch A, Heppner FL, Yonekawa Y, Merlo A, Frei K, Mariani L, Hofer S. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. Mol Cancer Ther. 2011 Jun;10(6):1102-12. doi: 10.1158/1535-7163.MCT-11-0048. Epub 2011 Apr 6.
Clinical trial NCT02949687: Surgical Treatment in Diabetic Patients With Grade 1 Obesity
Official title: Duodenal Ileal Interposition With Sleeve Gastrectomy and Selective Intra-Abdominal Denervation for Type 2 Diabetes Mellitus
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Diabetes Mellitus
Obesity
Keywords: ileal interposition
metabolic surgery
diabetes
intra abdominal selective denervation
Lead sponsor: Universidade Positivo
Sponsor class: OTHER
First posted: 2016-10-31
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Surgical Treatment in Diabetic Patients With Grade 1 Obesity

Detailed description: There will be a randomized clinical trial, non-blind, 1-arm treatment (Duodenal Ileal Interposition with Sleeve Gastrectomy and Selective Intra-Abdominal Denervation for Type 2 Diabetes Mellitus), including 40 research subjects with type 2 diabetes mellitus and obesity class I. In order to analise the effect on weight loss and glycemic control after 2 years of follow up

Eligibility criteria: Inclusion Criteria:

* Documented diagnosis of type 2 diabetes mellitus
* Both sexes were treated with oral antidiabetic agents and / or insulin except the current treatment with Glucagon-like peptide-1 (GLP-1) receptor agonists or dipeptidyl peptidase 4 inhibitors
* Stable antidiabetic medication within the last 8 weeks prior to randomization (V2), if therapy includes insulin, the average daily dose should not have changed by more than 10% in the past 8 weeks
* HbA1c\> 8.0%
* Age\> 20 years and \<60 years
* Body mass index (BMI) of 30 35 kg / m²
* Agree to sign the consent form

Exclusion Criteria:

* Type 1 diabetes mellitus (positive for anti-GAD), or GAD negative anti anti body with low β cell function (C-peptide after stimulation \<0.5 ng / ml)
* Current treatment with GLP-1 receptor agonist and / or dipeptidyl peptidase 4 inhibitors
* Recent vascular event (myocardial infarction, coronary angioplasty or stroke in the past 6 months)
* Malignant neoplasm
* Portal hypertension
* Inability to cooperate with segment
* Low capacity of understanding surgery
* Unrealistic expectations of the outcome
* Cognitive impairment
* Current pregnancy
* Moderate or severe mood disorder; severe anxiety; eating disorders (based on Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria)
* Chemical dependency or alcoholism (based on DSM-V criteria).

Primary outcomes:
measure: glycated hemoglobin(HbA1c) level of 6.0% or less, without the use of diabetes medications
timeFrame: 2 YEARS
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02025387: Physical Activity in Patients With Gynecological Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Women Who Underwent Midline Incision, Gynecological Surgery
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2014-01-01
Enrollment: 64
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Examine whether the measurement and feedback of physical activity increase the physical activity in women who underwent midline incision, gynecological surgery


Eligibility criteria: Inclusion Criteria:

* Midline incision, gynecological surgery

Exclusion Criteria:

* Cannot ambulate
* Anticipated long term ICU care
* Cannot wear accelerometer
* Anticipated discharge before postoperative day 5

Primary outcomes:
measure: Physical activity recovery rate
timeFrame: Postoperative day 4 and 5
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi do
Study officials:
References: